Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Octreotide Clear all
Terminated Phase 2 Interventional Results available

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

NCT01886287
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
Octreotide LAR
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 4 Interventional Results available

Ultrasound Guided Octreotide LAR Injection in Acromegaly

NCT00552071
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide LAR 30 MG Injection
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 18, 2026, 1:18 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

NCT00569127
View directory record Official record
Conditions
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate, Recombinant Interferon Alfa-2b
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
493
States / cities
Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 321 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04076462
View directory record Official record
Conditions
Acromegaly
Interventions
CAM2029 (octreotide subcutaneous depot), Matching placebo
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 1:18 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752
View directory record Official record
Conditions
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Interventions
[177Lu]Lu-DOTA-TATE, Octreotide LAR
Radiation · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
20
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 18, 2026, 1:18 AM EDT
Recruiting Phase 2 Interventional

Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome

NCT02019706
View directory record Official record
Conditions
ACTH, Cushing's Syndrome
Interventions
DOTATATE PET-CT, F-DOPA PET CT, CT scan, Routine MRI scan, Gated MRI scan, 68Ga-DOTATATE, 18F-DOPA
Radiation · Diagnostic Test · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 3 Interventional

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04125836
View directory record Official record
Conditions
Acromegaly
Interventions
CAM2029 (octreotide subcutaneous depot)
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 1 Interventional

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

NCT00049023
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
90Y-DOTA-tyr3-OCTREOTIDE
Radiation
Lead sponsor
O'Dorisio, M S
Other
Eligibility
2 Years to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 18, 2026, 1:18 AM EDT
Terminated Phase 3 Interventional

Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

NCT00642421
View directory record Official record
Conditions
Acromegaly
Interventions
C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg
Drug
Lead sponsor
Ambrilia Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Oct 18, 2026, 1:18 AM EDT
Terminated Phase 3 Interventional

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

NCT00006269
View directory record Official record
Conditions
Colorectal Cancer, Diarrhea
Interventions
irinotecan hydrochloride, octreotide acetate
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
East Hanover, New Jersey • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 1 Interventional

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

NCT00008073
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, octreotide acetate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 2 Interventional Results available

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

NCT00005906
View directory record Official record
Conditions
Lymphangioleiomyomatosis, Lymphangiomyomas, Pleural Effusions, Ascites
Interventions
Octreotide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2010 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

NCT00600886
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide, Octreotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 1:18 AM EDT
Not listed Phase 3 Interventional Results available

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

NCT03252353
View directory record Official record
Conditions
Acromegaly
Interventions
octreotide capsules, Matching placebo
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 2 Interventional Results available

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

NCT00171730
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 3 Interventional

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NCT00002967
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
106
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 2 Interventional Results available

Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients

NCT02916433
View directory record Official record
Conditions
Octreotide, Sputum
Interventions
Octreotide
Drug
Lead sponsor
Danbury Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 3 Interventional

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

NCT00131144
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 4 Interventional

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

NCT00050635
View directory record Official record
Conditions
Neoplasms, Diarrhea
Interventions
Sandostatin LAR Depot
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
34
States / cities
Burbank, California • Concord, California • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Oct 18, 2026, 1:18 AM EDT
Terminated Phase 1 Interventional

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

NCT00002947
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
Interventions
indium In 111 pentetreotide
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 2 Interventional Results available

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

NCT00853047
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Telotristat etiprate, Octreotide LAR Depot, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 18, 2026, 1:18 AM EDT
Withdrawn Phase 1 Interventional

Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

NCT06881888
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Octreotide (drug), Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 1:18 AM EDT
Completed Phase 3 Interventional

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

NCT00002864
View directory record Official record
Conditions
Breast Cancer
Interventions
octreotide acetate, tamoxifen citrate
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2010
U.S. locations
2
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 18, 2026, 1:18 AM EDT
Active, not recruiting Phase 3 Interventional

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

NCT05477576
View directory record Official record
Conditions
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
Interventions
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
32
States / cities
Phoenix, Arizona • Duarte, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 18, 2026, 1:18 AM EDT